ARIUS Announces Manufacturing Agreement with Avid Bioservices for CD44 Cancer Stem Cell Antibody
News Dec 06, 2007
Avid has begun manufacturing a supply of the drug for human clinical trials which ARIUS plans to initiate in 2008. ARIUS also announced it has scheduled a pre-IND meeting with the FDA that will take place in January.
"The initiation of manufacturing and the scheduling of our pre-IND meeting with the FDA in January reflect the significant progress we have made with our CD44 Cancer Stem Cell program," said Dr. David Young, President and Chief Executive Officer of ARIUS.
"Avid has proven expertise in the scale-up and manufacture of clinical and commercial grade antibodies and will provide us with a supply of our CD44 targeting drug to initiate human clinical trials in 2008, subject to the clearance of our IND by the FDA."
"This new manufacturing agreement is the result of the solid working relationship we have developed with the ARIUS team," said F. David King, Vice President, Business Development of Avid.
"Our goal is to form strategic partnerships with innovative life sciences companies like ARIUS, serving as a premier service provider by seamlessly integrating our experience and capabilities with our clients' needs."
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.